Literature DB >> 3970721

Potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced cytotoxicity in 9L cells by pretreatment with 6-thioguanine.

W J Bodell, W F Morgan, J Rasmussen, M E Williams, D F Deen.   

Abstract

9L Rat brain tumor cells were treated with 0.2 microM 6-thioguanine for 48 hr, which produced a 40% cell kill, a small (15%) inhibition of cell growth, and an accumulation of cells in S-phase. Maximum incorporation of [14C]6-thioguanine into cellular DNA occurred after 24 hr of incubation; 70% of the label was incorporated into DNA as 6-thio-2'-deoxyguanosine. Pretreatment of 9L cells for 48 hr with 0.2 microM 6-thioguanine potentiated the cytotoxicity of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) by 50% with a dose enhancement ratio of 1.5, and caused a 30% increase in the number of BCNU-induced sister chromatid exchanges (SCEs) and a 50% increase in DNA crosslinks formed, compared to treatment with BCNU alone. Used as a single agent, 6-thioguanine induced a significant number of SCEs. Results suggest that these effects may be related to the increased formation of DNA crosslinks, possibly as the result of the formation of S6-(2-chloroethyl)-6-thioguanine in cellular DNA.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3970721     DOI: 10.1016/0006-2952(85)90182-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Structural effect of the anticancer agent 6-thioguanine on duplex DNA.

Authors:  Jen Bohon; Carlos R de los Santos
Journal:  Nucleic Acids Res       Date:  2003-02-15       Impact factor: 16.971

2.  Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas.

Authors:  D C Smith; N A Vick; D L Trump; H S Friedman; A H Friedman; J Purvis; A Gauspari; S C Schold
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen.

Authors:  M D Prados; M S Edwards; J Rabbitt; K Lamborn; R L Davis; V A Levin
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

4.  Ask the Experts: How best to treat recurrent glioma.

Authors:  Victor Alan Levin
Journal:  CNS Oncol       Date:  2012-09

5.  Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.

Authors:  Tobias Walbert; Mark R Gilbert; Morris D Groves; Vinay K Puduvalli; W K Alfred Yung; Charles A Conrad; George C Bobustuc; Howard Colman; Sigmund H Hsu; B Nebiyou Bekele; Wei Qiao; Victor A Levin
Journal:  J Neurooncol       Date:  2010-07-23       Impact factor: 4.130

6.  Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts.

Authors:  A M Wang; G B Elion; H S Friedman; W J Bodell; D D Bigner; S C Schold
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Effect of 6-thioguanine on the stability of duplex DNA.

Authors:  Jen Bohon; Carlos R de los Santos
Journal:  Nucleic Acids Res       Date:  2005-05-19       Impact factor: 16.971

8.  Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.

Authors:  Eric T Wong; Edwin Lok; Kenneth D Swanson
Journal:  Cancer Med       Date:  2015-01-26       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.